Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs Unum Group Common Stock (UNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs Unum Group Common Stock — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.88 (market cap $42.21B), while Unum Group Common Stock trades at $91.42 (market cap $14.48B). The key difference: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) is far larger — about 2.9× Unum Group Common Stock's market cap, and Unum Group Common Stock pays the higher dividend (2.21%). Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 3 Days and Unum Group Common Stock for 0 Days on average.
| HLN | UNM | |
|---|---|---|
Market Cap | $42.21B | $14.48B |
Volume | 13,841,864 | 2,214,044 |
Sector | Health | Financials |
52-Week High | $11.27 | $96.57 |
52-Week Low | $8.70 | $70.66 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $52.02B | $18.04B |
Dividend Yield | 2.05% | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Haleon (HLN) trades at $9.44, down 0.63% today, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with $11.03B revenue, 14.55% net margin, and consistent earnings beats in recent quarters. Recent business developments include successful shelf space negotiations with major retailers and growth from weight-loss drug side-effect products.
The outlook remains positive with 75% analyst buy ratings and improving cash flow projections for 2026. Key opportunities include market share gains and margin expansion, while risks involve competitive pressures and potential margin compression. The stock presents a balanced risk-reward profile for investors seeking exposure to consumer healthcare.
Unum Group (UNM) trades at $92.05, down 0.5% with neutral technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Analyst consensus is positive with 50% buy ratings and a $101 price target representing 9.7% upside. The company maintains stable profitability with 5.31% net margin and recently announced a $1 billion share repurchase program to enhance shareholder returns.
UNM presents a balanced investment case with strong institutional support and shareholder-friendly capital returns, though earnings consistency remains a concern. The stock trades at reasonable valuations (P/E 21.36, P/S 1.15) with potential upside to analyst targets. Key risks include premium growth sustainability and claims experience volatility in the insurance operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.
Read more on HLN →About Unum Group Common Stock
Unum Group provides workplace benefits, including disability, life, accident, critical illness, dental, and vision insurance, along with leave management services. It serves employers through its Unum US, Unum International, and Colonial Life segments, distributing coverage via brokers and independent agents.
Read more on UNM →
